CJC-1295 no DAC: 0.1mg Ipamorelin: 0.15mg BPC-157: 0.25mg GHK-Cu: 1mg CJC-1295 no DAC: 0.1mg Ipamorelin: 0.15mg BPC-157: 0.25mg (optional second dose) TB-500: 2.5mg during loading, 2mg maintenance Tirzepatide: Per prescribed escalation schedule This protocol requires significant commitment to injection frequency but addresses all major concerns simultaneously
Estrogen has natural anti-inflammatory properties, so as estrogen falls, inflammation can increase
Granulocyte-colony stimulating factor (G-CSF) improves motor recovery in the rat impactor model for spinal cord injury
Studies demonstrate healing effects on: Stomach ulcers Intestinal damage Inflammatory bowel conditions Fistulas Rats with induced inflammatory bowel disease showed significant improvement with BPC-157 treatment
A wet face dilutes the serum and can make the layers that follow feel like they are sliding around
, stable in human gastric juice for more than 24 h (12, 13)), in the same dose-regimens, BPC 157 protected against various agents or procedures that would otherwise have lead to severe liver lesions (29-31) or CNS disturbances (16-23)
